Malaria vax passes hurdle

A malaria vaccine for infants and children -- the group most vulnerable to the disease -- may be heading to phase III trials, according to authors of two studies published online today (Dec. 8) in the New England Journal of Medicine. "The research results show we are one important step closer to malaria joining diseases like small pox or polio that have been either controlled or eliminated by vaccine," said Christian Loucq, director of linkurl:PATH Malaria Vaccine Initiative;http://path.org/ du

Jennifer Evans
Dec 7, 2008
A malaria vaccine for infants and children -- the group most vulnerable to the disease -- may be heading to phase III trials, according to authors of two studies published online today (Dec. 8) in the New England Journal of Medicine. "The research results show we are one important step closer to malaria joining diseases like small pox or polio that have been either controlled or eliminated by vaccine," said Christian Loucq, director of linkurl:PATH Malaria Vaccine Initiative;http://path.org/ during a press conference this morning. The search for a malaria vaccine has been stymied by the complex nature of the malaria parasite, its ability to evade the immune system, and constant exposure to malaria in regions of Africa, said Joe Cohen, Vice President of R&D for Vaccines for Emerging Diseases & HIV at GlaxoSmithKline(GSK). Cohen co-invented the vaccine, RTS,S/AS, in 1987, but it took more than a decade to make the...
haemophilus influenzae



Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?